Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
- Antibody
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27151
License Grant
The University has granted us the exclusive, worldwide right to use and practice a method owned by University of heated perfusion of chemotherapy drug in the treatment of intraperitoneal and other cancers.
License Property
The system delivers perfusion-induced hyperthermia, a form of whole-body hyperthermia, for treatment of patients suffering from HIV and metastatic non-small cell lung cancer. Can also be used to administer regional hyperthermia in combination with surgery and chemotherapy for treatment of patients with advanced gastrointestinal and ovarian cancers.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 325366
License Grant
Through a partnership with a third party, Licensee develops and/or commercialize sugemalimab for worldwide sales which results in royalty payments to Licensor.
License Property
Sugemalimab (CS1001), an OmniAb-derived anti-PD-L1 monoclonal antibody used in combination with chemotherapy for lung cancer.
Field of Use
Field of use is for the first-line treatment of advanced squamous and non-squamous non-small cell lung cancer (“NSCLCâ€).
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. The main subtypes of NSCLC Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
IPSCIO Record ID: 26726
License Grant
In the second quarter of 1997, we obtained an exclusive license from the University for the rights to such formulation. In cooperation with researchers at the University, we have developed a new formulation of paclitaxel, which does not contain Cremophor and ethanol, ingredients used in the currently approved generic formulation.
Paclitaxel is an anticancer compound used for the treatment of ovarian, breast, small cell lung cancers and AIDS related Kaposi sarcomas.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 28485
License Grant
The Licensee entered into an exclusive, worldwide License Agreement with a University for the AC Technology.
License Property
The AC Technology is based on the concept of haptenization.
Our AC Technology utilizes the patient's tumor as the basis for a therapeutic vaccine. By collecting and processing the cancer cells extracted from a patient's tumor most typically during the course of the first line of treatment, surgical tumor rescission, and then treating them with a hapten called dinitrophenol ('DNP'), a vaccine is prepared and then given back to the patient in an effort to elicit a systemic immune response to the unmodified, native cancer cells.
Field of Use
The Licensee is a development stage biotechnology company specializing primarily in the development and future commercialization of individualized cancer vaccines. Our proposed vaccines consist of autologous (the patient's own) cancer cells that have been treated with a chemical ('haptenized') to make them more visible to the patient's immune system. Our previous clinical trials for the AC Vaccine have concentrated on melanoma and ovarian carcinoma, which are our primary indications, and non-small cell lung cancer.
IPSCIO Record ID: 321858
License Grant
This amendment increases the royalties for dostarlimab and adds terms for Zejula.
License Property
Dostarlimab is an anti-PD-1 antagonist antibody.
Zejula TM is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor.
Field of Use
Dostarlimab is under development for multiple oncological disorders, including endometrial cancer, non-small cell lung cancer, ovarian cancer, colorectal cancer and mismatch repair deficient solid tumors.
Zejula, which has received US approval for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
IPSCIO Record ID: 182116
License Grant
The parties entered an agreement for one of the Licensors programs.
License Property
This program is for MM-121 or Seribantumab. Seribantumab is an antibody-drug that targets ErbB3 that was developed using the Selexis SUREtechnology Platform.
Field of Use
Licensee is currently conducting a Phase 2 trial of seribantumab (MM-121) in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer whose disease has progressed following immunotherapy.
IPSCIO Record ID: 367327
License Grant
In consideration of the equity in the Canadian Licensee, the royalty payments reserved herein, and the covenants on the part of the Licensee contained herein, the Canadian University hereby
(a) grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement; and
(b) grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.
The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.
License Property
Technology relating to antisense oligonucleotide therapy for the treatment of prostate cancer and other cancers.
U.S. Provisional filed July 19, 1999 – Serial No. 60/144,495
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone–Regulated Tumors
Full U.S. application flied July 19, 2000 – Serial No. 09/619,908
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors
PCT filed July 19, 2000 – Serial No. PCT/CA00/00853
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors
Field of Use
Field of use is for the treatment of prostate cancer and other cancers.
OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
